Literature DB >> 11493021

Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease.

J F Poduslo1, G L Curran, T M Wengenack, B Malester, K Duff.   

Abstract

The permeability of albumin, insulin, and human A beta 1--40 at the blood-brain barrier (BBB) was determined in the normal adult mouse (B6/SJL) and in the double transgenic Alzheimer mouse (APP, PS1) by using an I.V. bolus injection technique to quantify the permeability coefficient-surface area (PS) product for each protein after correction for the residual plasma volume (V(p)) occupied by the protein in the blood vessels of different brain regions using a second aliquot of the same protein radiolabeled with a different isotope of iodine ((125)I vs (131)I) as a vascular space marker. This technology for quantifying BBB permeability of proteins was adapted from the rat to the mouse and involved catheterizing the femoral artery and vein of the mouse instead of the brachial artery and vein as for the rat. Because of the smaller blood volume in the mouse, serial sampling (20 microl) of blood from the femoral artery of the mouse was performed and directly TCA precipitated to generate a whole blood washout curve for the intact protein. When similar blood sampling techniques were used in the rat, the PS values for albumin and insulin at the BBB were similar in these two species. In the double transgenic mouse, the V(p) values for albumin were significantly increased 1.4- to 1.6-fold in five of six brain regions compared to the normal adult mouse, which indicated increased adherence of albumin to vessel walls. As a result, the PS values were significantly decreased, from 1.4- to 3.2-fold, which likely reflected decreased transport of albumin by passive diffusion. In contrast, insulin, which is taken up into the brain by a receptor-mediated transport mechanism at the BBB, showed no significant difference in the V(p) values but a significant increase in the PS values in four of six brain regions. This suggests a compensatory mechanism in the Alzheimer's transgenic brain whereby there is an increased permeability to insulin at the BBB. Surprisingly, there was no significant difference in the V(p) or PS values for human A beta 1--40 at the BBB in the double transgenic Alzheimer mouse at 24, 32, or 52 weeks of age, when there is both significant A beta levels in the plasma and amyloid burden in the brains of these animals. These data suggest that there is not an alteration in permeability to human A beta 1--40 at the BBB with increasing amyloid burden in the double transgenic Alzheimer mouse. Although these observations suggest structural alterations at the BBB, they do not support the concept of extensive BBB damage with substantial increases in BBB permeability in Alzheimer's disease. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493021     DOI: 10.1006/nbdi.2001.0402

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  32 in total

Review 1.  Routes for the delivery of insulin to the central nervous system: A comparative review.

Authors:  Elizabeth M Rhea; Therese S Salameh; William A Banks
Journal:  Exp Neurol       Date:  2018-11-27       Impact factor: 5.330

Review 2.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugated antibody fragment against fibrillar Abeta42 for magnetic resonance molecular imaging.

Authors:  Muthu Ramakrishnan; Thomas M Wengenack; Karunya K Kandimalla; Geoffry L Curran; Emily J Gilles; Marina Ramirez-Alvarado; Joseph Lin; Michael Garwood; Clifford R Jack; Joseph F Poduslo
Journal:  Pharm Res       Date:  2008-04-29       Impact factor: 4.200

4.  Unexpected amount of blood-borne protein enters the young brain.

Authors:  Roeben N Munji; Richard Daneman
Journal:  Nature       Date:  2020-07       Impact factor: 49.962

Review 5.  Insulin in the brain: there and back again.

Authors:  William A Banks; Joshua B Owen; Michelle A Erickson
Journal:  Pharmacol Ther       Date:  2012-07-17       Impact factor: 12.310

Review 6.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

7.  Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis.

Authors:  Andrew L Zhou; Suresh K Swaminathan; Geoffry L Curran; Joseph F Poduslo; Val J Lowe; Ling Li; Karunya K Kandimalla
Journal:  J Pharmacol Exp Ther       Date:  2019-04-10       Impact factor: 4.030

8.  Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain.

Authors:  Suresh Kumar Swaminathan; Kristen M Ahlschwede; Vidur Sarma; Geoffry L Curran; Rajesh S Omtri; Teresa Decklever; Val J Lowe; Joseph F Poduslo; Karunya K Kandimalla
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

Review 9.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 10.  In vitro cerebrovascular modeling in the 21st century: current and prospective technologies.

Authors:  Christopher A Palmiotti; Shikha Prasad; Pooja Naik; Kaisar M D Abul; Ravi K Sajja; Anilkumar H Achyuta; Luca Cucullo
Journal:  Pharm Res       Date:  2014-08-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.